BioHarvest Sciences Inc. announced in September 2025 the successful large-scale production of plant-based exosomes in its bioreactors. This achievement represents a significant technological breakthrough for the company's Botanical Synthesis platform.
Exosomes are nano-sized extracellular vesicles known for their enhanced absorption and bioavailability, making them highly valuable for various applications. This development opens new potential revenue streams for BioHarvest, both through its proprietary product pipeline and its CDMO services.
The ability to produce exosomes at an industrial scale positions BioHarvest to capitalize on emerging opportunities in nutraceuticals, pharmaceuticals, and other high-value industries. This innovation further demonstrates the versatility and advanced capabilities of the company's patented technology.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.